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Jhaveri et al published a case report entitled “Praluent (Aliro-
cumab)-Induced Renal Injury” in a recent issue of the Journal
of Pharmacy Practice.1 The authors report a case of a 62-year-
old female patient with chronic hypertensive nephropathy who
experienced acute renal injury while treated with Praluent (alir-
ocumab). While the information provided might be compatible
with a possible causal role of alirocumab, several questions or
comments can be raised/remain open for the discussion with
the authors.
Although the patient had chronic kidney disease stage IV,
she was treated with rosuvastatin 40 mg daily, which exceeds
product indication by 4-fold.2 However, the possible role of
rosuvastatin in inducing the acute renal injury has not been
discussed. With regard to the hypothetical impact of alirocu-
mab on serum creatinine levels, it appears from Figure 2 of the
article that the increase in serum creatinine levels had started
prior to the initiation of alirocumab. It would have been
important to provide the evolution of this parameter over time
rather than providing only the baseline and the maximum
value. Also, other parameters such as creatine kinase values
and urinary myoglobin, if available, would have been helpful
to allow for additional assessment of the potential contribu-
tion to rosuvastatin-induced rhabdomyolysis and therefore
kidney damage. In addition to rhabdomyolysis-induced acute
kidney injury, rosuvastatin has been associated nonrhabdo-
myolysis causes of acute kidney injury. These nonrhabdo-
myolysis causes of acute kidney injury with rosuvastatin
include renal tubular toxicity and interstitial nephritis.3,4,5
The frequency of acute kidney injury with statin therapy was
reported in a large retrospective observational analysis of 7
administrative databases from Canada and 2 databases from
the United Kingdom and United States which evaluated the
risk of acute kidney injury in patients newly treated with high-
potency statins that included rosuvastatin dosages 10 mg.6
Of more than 2 million new stain users, high-potency statin
use was associated with a 1.34-fold (95% confidence interval:
1.25-1.43) higher fixed effect rate ratio of hospitalization for
acute kidney injury than patients treated with low-intensity
statin therapy.
It should be noted that the patient was also taking ramipril, a
drug known to possibly play a role in the onset of acute renal
injury. The information on the timing of action taken on rami-
pril in relationship to the onset of acute renal injury is missing.
Regarding the medical history of this patient, the cardiovascu-
lar status of the patient was not characterized more precisely
than by stating that the patient had a medical history of cardiac
disease. No clear information was provided on the duration of
the disease and on its renovascular expression. It remains
unknown whether bilateral renal artery stenosis was excluded.
The authors propose a list of relevant alternative nondrug
causes that they have ruled out; however, this list does not
appear to be exhaustive. Other plausible causes of acute renal
injury, such as infectious disease or ischemic causes, have not
been evaluated. As already mentioned, the patient suffered
from cardiac disease, without further diagnostic precision and
without further information on her hemodynamic situation at
the time of acute deterioration of renal dysfunction. It was
unknown whether the patient had diabetes.
Another point to consider is that the authors mentioned,
without providing precise values reported on a time scale, that
the patient’s serum creatinine values returned to baseline about
6 weeks after the withdrawal of alirocumab. When considering
the pharmacokinetic profile of alirocumab, it is relevant to note
that 6 weeks after withdrawal of alirocumab, a residual level of
the drug is known to be present in the patient’s body.
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Finally, while assessing causality, the authors referred to the
Naranjo algorithm yielding a score of 6 for a causal involve-
ment of alirocumab in this case. Using the strict application of
the information available in the article results in the score of 3,
and this would be interpreted as “possibly related” rather than
“probably related” to alirocumab. In addition, beyond this dif-
ference of scoring, it should be highlighted that the Naranjo
algorithm has been previously challenged as a tool lacking
validity and reproducibility in the attribution of causality, for
example, in the assessment of hepatotoxicity.7,8 A more robust
algorithm for causality assessment should therefore be consid-
ered, once the relevant missing information allowing a full
assessment of this case has been made available by the authors.
We consider this case of renal injury resulted from excessive
dosing of rosuvastatin, which has been previously associated
with acute kidney injury. The temporal rise in serum creatinine
occurred before initiation of alirocumab, supporting renal toxi-
city before the introduction of the PCSK9 inhibitor.
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